Andrzej Grski

List of Publications by Year in Descending Order

159 papers	4,891 citations	39 h-index	64 g-index
180 ext. papers	5,973 ext. citations	4.5 avg, IF	5.74 L-index

#	Paper	IF	Citations
159	Phage therapy of wound-associated infections.. *Folia Microbiologica*, **2022**, 67, 193	2.8	2
158	The contribution of phage therapy to medical knowledge.. *Journal of Global Antimicrobial Resistance*, **2022**,	3.4	2
157	Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.. *Journal of Biomedical Science*, **2022**, 29, 23	13.3	5
156	A Thorough Synthesis of Phage Therapy Unit Activity in Poland□Its History, Milestones and International Recognition. *Viruses*, **2022**, 14, 1170	6.2	1
155	Bronis□wa Fejgin (1883-1943): Forgotten Important Contributor to International Microbiology and Phage Therapy. *Antibiotics*, **2021**, 10,	4.9	1
154	Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allotransplantation. *Transplantation*, **2021**, 105, 1449-1458	1.8	5
153	The Role of Antibiotic Resistant in the Pathogenesis of Urinary Tract Infection and the Potential of Its Treatment with the Use of Bacteriophage Therapy. *Antibiotics*, **2021**, 10,	4.9	7
152	Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. *BioDrugs*, **2021**, 35, 255-280	7.9	10
151	Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections. *Antibiotics*, **2021**, 10,	4.9	3
150	Temperate Bacteriophages-The Powerful Indirect Modulators of Eukaryotic Cells and Immune Functions. *Viruses*, **2021**, 13,	6.2	1
149	Public availability of results of ClinicalTrials.gov-registered expanded access studies. *British Journal of Clinical Pharmacology*, **2021**,	3.8	1
148	Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies. *Frontiers in Immunology*, **2021**, 12, 639570	8.4	7
147	Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. *Transplant Infectious Disease*, **2021**, 23, e13391	2.7	22
146	Ethics codes and medical decision making. *Patient Education and Counseling*, **2021**, 104, 1312-1316	3.1	2
145	Anti-phage serum antibody responses and the outcome of phage therapy. *Folia Microbiologica*, **2021**, 66, 127-131	2.8	6
144	Anti-biofilm activity of bacteriophages and lysins in chronic rhinosinusitis. *Acta Virologica*, **2021**, 65, 127-140	1.0	3
143	Animal Models in the Evaluation of the Effectiveness of Phage Therapy for Infections Caused by Gram-Negative Bacteria from the ESKAPE Group and the Reliability of Its Use in Humans. *Microorganisms*, **2021**, 9,	4.9	8

142	Bacteriophage Pharmacology and Immunology **2021**, 295-339		0
141	ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study. *Journal of Medical Internet Research*, **2021**, 23, e26890	7.6	0
140	Conflicts of interest in oncology expanded access studies. *International Journal of Cancer*, **2021**, 149, 1809-1816	7.5	0
139	Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. *Antibiotics*, **2021**, 10,	4.9	1
138	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia **2021**, 921-951		1
137	The preliminary association study of osteopontin 707 C/T polymorphism with systemic lupus erythematosus in a Polish population. *Postepy Dermatologii I Alergologii*, **2020**, 37, 190-194	1.5	
136	Phage Therapy in Poland - a Centennial Journey to the First Ethically Approved Treatment Facility in Europe. *Frontiers in Microbiology*, **2020**, 11, 1056	5.7	19
135	Natural and Induced Antibodies Against Phages in Humans: Induction Kinetics and Immunogenicity for Structural Proteins of PB1-Related Phages. *Phage*, **2020**, 1, 91-99	1.8	7
134	Microbiota in organ transplantation: An immunological and therapeutic conundrum?. *Cellular Immunology*, **2020**, 351, 104080	4.4	2
133	Bacteriophages and Lysins in Biofilm Control. *Virologica Sinica*, **2020**, 35, 125-133	6.4	30
132	Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials. *British Journal of Clinical Pharmacology*, **2020**, 86, 679-686	3.8	5
131	The effects of T4 and A5/80 phages on the expression of immunologically important genes in differentiated Caco-2 cells*. *Postepy Higieny I Medycyny Doswiadczalnej*, **2020**, 74, 371-376	0.3	3
130	Sepsis, Phages, and COVID-19. *Pathogens*, **2020**, 9,	4.5	3
129	Phage Prevalence in the Human Urinary Tract-Current Knowledge and Therapeutic Implications. *Microorganisms*, **2020**, 8,	4.9	8
128	Phage Therapy: Towards a Successful Clinical Trial. *Antibiotics*, **2020**, 9,	4.9	30
127	Ethics framework for treatment use of investigational drugs. *BMC Medical Ethics*, **2020**, 21, 116	2.9	2
126	Phages in Therapy and Prophylaxis of American Foulbrood - Recent Implications From Practical Applications. *Frontiers in Microbiology*, **2020**, 11, 1913	5.7	4
125	Phages as a Cohesive Prophylactic and Therapeutic Approach in Aquaculture Systems. *Antibiotics*, **2020**, 9,	4.9	7

124	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. *Frontiers in Microbiology*, **2020**, 11, 591021	5.7	5
123	The Presence of Bacteriophages in the Human Body: Good, Bad or Neutral?. *Microorganisms*, **2020**, 8,	4.9	3
122	Phage therapy: Current status and perspectives. *Medicinal Research Reviews*, **2020**, 40, 459-463	14.4	56
121	Bacteriophage Interactions With Epithelial Cells: Therapeutic Implications. *Frontiers in Microbiology*, **2020**, 11, 631161	5.7	7
120	Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin. *British Journal of Clinical Pharmacology*, **2019**, 85, 2448-2449	3.8	1
119	Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii. *Virologica Sinica*, **2019**, 34, 347-357	6.4	15
118	Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. *European Journal of Internal Medicine*, **2019**, 65, 12-16	3.9	16
117	Bacteriophages engineered to display foreign peptides may become short-circulating phages. *Microbial Biotechnology*, **2019**, 12, 730-741	6.3	23
116	Inhibitory Effects of Bacteriophage Preparations on Adenoviral Replication. *Intervirology*, **2019**, 62, 37-44	1.5	4
115	The fall and rise of phage therapy in modern medicine. *Expert Opinion on Biological Therapy*, **2019**, 19, 1115-1117	5.4	11
114	Selenium-containing polysaccharides from Lentinula edodes-Biological activity. *Carbohydrate Polymers*, **2019**, 223, 115078	10.3	12
113	Factors determining phage stability/activity: challenges in practical phage application. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 583-606	5.5	26
112	Long-term outcome of renal transplantation: a 10-year follow-up of 765 recipients. *Polish Archives of Internal Medicine*, **2019**, 129, 476-483	1.9	1
111	The effects of bacteriophages on the expression of genes involved in antimicrobial immunity*. *Postepy Higieny I Medycyny Doswiadczalnej*, **2019**, 73, 414-420	0.3	4
110	Ethics of Phage Therapy **2019**, 379-385		
109	Humoral Immune Response to Phage-Based Therapeutics **2019**, 123-143		1
108	Phage Therapy in Orthopaedic Implant-Associated Infections **2019**, 189-211		2
107	Phage penetration of eukaryotic cells: practical implications. *Future Virology*, **2019**, 14, 745-760	2.4	12

106	Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered. *Frontiers in Immunology*, **2019**, 10, 2607	8.4	20
105	The Role of the Virome in the Gut-Liver Axis **2019**, 121-131		
104	Ethics codes and use of new and innovative drugs. *British Journal of Clinical Pharmacology*, **2019**, 85, 501-507	3.8	14
103	Perspectives of Phage Therapy in Non-bacterial Infections. *Frontiers in Microbiology*, **2018**, 9, 3306	5.7	30
102	Expanded access: growing importance to public health. *Journal of Epidemiology and Community Health*, **2018**, 72, 557-558	5.1	1
101	Phage therapy in allergic disorders?. *Experimental Biology and Medicine*, **2018**, 243, 534-537	3.7	6
100	Therapeutic potential of phages in autoimmune liver diseases. *Clinical and Experimental Immunology*, **2018**, 192, 1-6	6.2	11
99	"Phage Transplantation in Allotransplantation": Possible Treatment in Graft-Versus-Host Disease?. *Frontiers in Immunology*, **2018**, 9, 941	8.4	5
98	Phage Therapy: Beyond Antibacterial Action. *Frontiers in Medicine*, **2018**, 5, 146	4.9	16
97	Perspectives of Phage-Eukaryotic Cell Interactions to Control Epstein-Barr Virus Infections. *Frontiers in Microbiology*, **2018**, 9, 630	5.7	7
96	Phage Therapy in Prostatitis: Recent Prospects. *Frontiers in Microbiology*, **2018**, 9, 1434	5.7	12
95	Phage Therapy: What Have We Learned?. *Viruses*, **2018**, 10,	6.2	68
94	Bacteriophage Pharmacology and Immunology **2018**, 1-45		0
93	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia **2018**, 1-31		8
92	Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. *Cellular and Molecular Life Sciences*, **2018**, 75, 589-595	10.3	16
91	Use of a Regression Model to Study Host-Genomic Determinants of Phage Susceptibility in MRSA. *Antibiotics*, **2018**, 7,	4.9	4
90	Phages and immunomodulation. *Future Microbiology*, **2017**, 12, 905-914	2.9	87
89	Can phage therapy solve the problem of recalcitrant chronic rhinosinusitis?. *Future Microbiology*, **2017**, 12, 1427-1442	2.9	7

88	Ethics review in compassionate use. *BMC Medicine*, **2017**, 15, 136	11.4	24
87	Delivering phage therapy per os: benefits and barriers. *Expert Review of Anti-Infective Therapy*, **2017**, 15, 167-179	5.5	16
86	Antiphage activity of sera during phage therapy in relation to its outcome. *Future Microbiology*, **2017**, 12, 109-117	2.9	59
85	Bacteriophages in the gastrointestinal tract and their implications. *Gut Pathogens*, **2017**, 9, 44	5.4	60
84	A3R Phage and Staphylococcus aureus Lysate Do Not Induce Neutrophil Degranulation. *Viruses*, **2017**, 9,	6.2	14
83	Phage-Phagocyte Interactions and Their Implications for Phage Application as Therapeutics. *Viruses*, **2017**, 9,	6.2	38
82	The Potential of Phage Therapy in Sepsis. *Frontiers in Immunology*, **2017**, 8, 1783	8.4	25
81	Prospects of Phage Application in the Treatment of Acne Caused by. *Frontiers in Microbiology*, **2017**, 8, 164	5.7	20
80	Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80. *Frontiers in Microbiology*, **2017**, 8, 467	5.7	37
79	Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process. *BioMed Research International*, **2017**, 2017, 3612015	3	24
78	Structure of Post-Transplant Care in a Single Transplant Center. *Annals of Transplantation*, **2016**, 21, 194-9	1.4	1
77	T4 Phage Tail Adhesin Gp12 Counteracts LPS-Induced Inflammation In Vivo. *Frontiers in Microbiology*, **2016**, 7, 1112	5.7	55
76	Bacteriophage Procurement for Therapeutic Purposes. *Frontiers in Microbiology*, **2016**, 7, 1177	5.7	76
75	The Effects of T4 and A3/R Bacteriophages on Differentiation of Human Myeloid Dendritic Cells. *Frontiers in Microbiology*, **2016**, 7, 1267	5.7	8
74	LPS-Activated Monocytes Are Unresponsive to T4 Phage and T4-Generated Escherichia coli Lysate. *Frontiers in Microbiology*, **2016**, 7, 1356	5.7	8
73	Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases. *Frontiers in Microbiology*, **2016**, 7, 1515	5.7	97
72	Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. *Frontiers in Microbiology*, **2016**, 7, 1681	5.7	51
71	Phages targeting infected tissues: novel approach to phage therapy. *Future Microbiology*, **2015**, 10, 199-204	2.9	35

70	T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro. *Future Microbiology*, **2015**, 10, 453-60	2.9	20
69	Mammalian Host-Versus-Phage immune response determines phage fate in vivo. *Scientific Reports*, **2015**, 5, 14802	4.9	140
68	The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes. *Journal of Immunology Research*, **2015**, 2015, 482863	4.5	34
67	Quality and safety requirements for sustainable phage therapy products. *Pharmaceutical Research*, **2015**, 32, 2173-9	4.5	129
66	Toll-Like Receptor 4 Gene Polymorphism C1196T in Polish Women with Postmenopausal Osteoporosis - Preliminary Investigation. *Advances in Clinical and Experimental Medicine*, **2015**, 24, 239-43	1.8	5
65	Immunogenicity studies of proteins forming the T4 phage head surface. *Journal of Virology*, **2014**, 88, 12551-7	6.6	86
64	In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. *Journal of Medical Microbiology*, **2014**, 63, 1055-1065	3.2	47
63	Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. *Future Microbiology*, **2014**, 9, 861-9	2.9	20
62	Phage neutralization by sera of patients receiving phage therapy. *Viral Immunology*, **2014**, 27, 295-304	1.7	123
61	Taking bacteriophage therapy seriously: a moral argument. *BioMed Research International*, **2014**, 2014, 621316	3	27
60	Possible use of bacteriophages active against Bacillus anthracis and other B. cereus group members in the face of a bioterrorism threat. *BioMed Research International*, **2014**, 2014, 735413	3	9
59	Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. *Viruses*, **2014**, 6, 2551-70	6.2	63
58	Molecular imaging of T4 phage in mammalian tissues and cells. *Bacteriophage*, **2014**, 4, e28364		24
57	Characterising the biology of novel lytic bacteriophages infecting multidrug resistant Klebsiella pneumoniae. *Virology Journal*, **2013**, 10, 100	6.1	79
56	Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. *Wound Repair and Regeneration*, **2013**, 21, 595-603	3.6	71
55	Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. *Cell Transplantation*, **2013**, 22, 1591-612	4	188
54	A novel approach for separating bacteriophages from other bacteriophages using affinity chromatography and phage display. *Scientific Reports*, **2013**, 3, 3220	4.9	25
53	Influence of bacteriophage preparations on intracellular killing of bacteria by human phagocytes in vitro. *Viral Immunology*, **2013**, 26, 150-62	1.7	10

52	T4 phage and its head surface proteins do not stimulate inflammatory mediator production. *PLoS ONE*, **2013**, 8, e71036	3.7	57
51	Influence of bacteriophage preparations on migration of HL-60 leukemia cells in vitro. *Anticancer Research*, **2013**, 33, 1569-74	2.3	3
50	Phage as a modulator of immune responses: practical implications for phage therapy. *Advances in Virus Research*, **2012**, 83, 41-71	10.7	160
49	Clinical aspects of phage therapy. *Advances in Virus Research*, **2012**, 83, 73-121	10.7	220
48	The phage therapy paradigm: pr[illegible]porter or sur-mesure?. *Pharmaceutical Research*, **2011**, 28, 934-7	4.5	188
47	Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives. *BioDrugs*, **2011**, 25, 347-55	7.9	21
46	The perspectives of the application of phage therapy in chronic bacterial prostatitis. *FEMS Immunology and Medical Microbiology*, **2010**, 60, 99-112		42
45	Fusion to cell-penetrating peptides will enable lytic enzymes to kill intracellular bacteria. *Medical Hypotheses*, **2010**, 74, 164-6	3.8	14
44	The effects of T4 and A3/R phage preparations on whole-blood monocyte and neutrophil respiratory burst. *Viral Immunology*, **2010**, 23, 541-4	1.7	17
43	Bacteriophages and cancer. *Archives of Microbiology*, **2010**, 192, 315-20	3	40
42	Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. *Medical Microbiology and Immunology*, **2010**, 199, 71-9	4	17
41	The effects of staphylococcal bacteriophage lysates on cancer cells in vitro. *Clinical and Experimental Medicine*, **2010**, 10, 81-5	4.9	7
40	The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. *BMC Microbiology*, **2009** , 9, 13	4.5	12
39	Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. *BMC Microbiology*, **2009**, 9, 169	4.5	26
38	Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. *Clinical and Experimental Medicine*, **2009**, 9, 93-100	4.9	24
37	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. *Clinical and Experimental Medicine*, **2009**, 9, 303-12	4.9	44
36	Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report. *Folia Microbiologica*, **2009**, 54, 457-61	2.8	61
35	The potential of phage therapy in bacterial infections of the eye. *Ophthalmologica*, **2009**, 223, 162-5	3.7	19

34	Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. *Anticancer Research*, **2009**, 29, 2361-70	2.3	3
33	My remembrance of Professor Tadeusz Orłowski **2009**, 119, 289-91		
32	Bacteriophage therapy for the treatment of infections. *Current Opinion in Investigational Drugs*, **2009**, 10, 766-74		74
31	Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. *Virus Research*, **2008**, 131, 233-42	6.4	63
30	Is phage therapy acceptable in the immunocompromised host?. *International Journal of Infectious Diseases*, **2008**, 12, 466-71	10.5	54
29	Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. *Immunology Letters*, **2008**, 116, 24-32	4.1	35
28	The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice. *Postepy Higieny I Medycyny Doswiadczalnej*, **2008**, 62, 42-6	0.3	7
27	Bacteriophage therapy in children: facts and prospects. *Medical Science Monitor*, **2008**, 14, RA126-32	3.2	22
26	Hoc protein regulates the biological effects of T4 phage in mammals. *Archives of Microbiology*, **2007** , 187, 489-98	3	38
25	Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. *Postepy Higieny I Medycyny Doswiadczalnej*, **2007**, 61, 461-5	0.3	39
24	Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker--case report. *Folia Microbiologica*, **2006**, 51, 236-8	2.8	42
23	Bacteriophage endolysins as a novel class of antibacterial agents. *Experimental Biology and Medicine*, **2006**, 231, 366-77	3.7	227
22	Bacteriophage translocation. *FEMS Immunology and Medical Microbiology*, **2006**, 46, 313-9		149
21	Effects of bacteriophages on free radical production and phagocytic functions. *Medical Microbiology and Immunology*, **2006**, 195, 143-50	4	60
20	Introduction: the responsible conduct of basic and clinical research. *Science and Engineering Ethics*, **2006**, 12, 3-4	3.1	
19	Activity of bacteriophages in murine tumor models depends on the route of phage administration. *Oncology Research*, **2005**, 15, 183-7	4.8	13
18	Bacterial viruses against viruses pathogenic for man?. *Virus Research*, **2005**, 110, 1-8	6.4	33
17	The potential role of endogenous bacteriophages in controlling invading pathogens. *Cellular and Molecular Life Sciences*, **2005**, 62, 511-9	10.3	115

16	The ethics of intellectual property rights in biomedicine and biotechnology: an introduction. *Science and Engineering Ethics*, **2005**, 11, 4-6	3.1	1
15	Nec Soli Cedit (article dedicated to Professor Ludwik Hirszfeld). *Postepy Higieny I Medycyny Doswiadczalnej*, **2005**, 59, 570-2	0.3	
14	Introduction to the proceedings of an international conference Placebo: Its action and place in health research today Warsaw, Poland, 12?13 April, 2003. *Science and Engineering Ethics*, **2004**, 10, 3-4	3.1	
13	Placebo: its action and place in health research today. *Science and Engineering Ethics*, **2004**, 10, 3-4	3.1	
12	Preparation of endotoxin-free bacteriophages. *Cellular and Molecular Biology Letters*, **2004**, 9, 253-9	8.1	65
11	Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. *Anticancer Research*, **2004**, 24, 3991-5	2.3	31
10	New insights into the possible role of bacteriophages in host defense and disease. *Medical Immunology*, **2003**, 2, 2		54
9	Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. *Transplantation Proceedings*, **2003**, 35, 1385-6	1.1	74
8	Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation. *Cellular and Molecular Biology Letters*, **2003**, 8, 699-711	8.1	15
7	Extracellular matrix proteins dependent apoptosis of T Cells in women with a history of recurrent spontaneous abortion. *American Journal of Reproductive Immunology*, **2002**, 48, 151-151	3.8	
6	Enhanced T cells interactions with extracellular matrix proteins in infertile women with endometriosis. *Immunology Letters*, **2002**, 81, 65-70	4.1	8
5	Effect of phage therapy on the turnover and function of peripheral neutrophils. *FEMS Immunology and Medical Microbiology*, **2002**, 34, 135-8		30
4	Low-dose heparin: a novel approach in immunosuppression. *Transplant International*, **1994**, 7 Suppl 1, S567-9	3	5
3	Immunomodulatory action of human recombinant erythropoietin in man. *Immunology Letters*, **1993**, 35, 271-5	4.1	21
2	Immunomodulating activity of heparin. *FASEB Journal*, **1991**, 5, 2287-91	0.9	55
1	Enzybiotics and their Potential Applications in Medicine1-26		1